Related references
Note: Only part of the references are listed.Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice
Xiaomeng Hu et al.
NATURE COMMUNICATIONS (2023)
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Lukas Kraehenbuehl et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment
Alain E. Andrea et al.
FRONTIERS IN IMMUNOLOGY (2022)
Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy
Jin Wang et al.
FRONTIERS IN IMMUNOLOGY (2022)
Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer
Yan Xu et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells
Mako Tomogane et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia
Rajkumar Ganesan et al.
LEUKEMIA (2021)
Cancer immunotherapy: A comprehensive appraisal of its modes of application
Mira Hoteit et al.
ONCOLOGY LETTERS (2021)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
'Off-the-shelf' allogeneic CAR T cells: development and challenges
S. Depil et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells
Marc Rigau et al.
SCIENCE (2020)
Butyrophilin-2A1 Directly Binds Germline-Encoded Regions of the Vγ9Vδ2 TCR and Is Essential for Phosphoantigen Sensing
Mohindar M. Karunakaran et al.
IMMUNITY (2020)
Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy
Wentao Li et al.
IMMUNITY (2020)
Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
Meir Rozenbaum et al.
FRONTIERS IN IMMUNOLOGY (2020)
Cancer immunotherapy harnessing γδ T cells and programmed death-1
Yoshimasa Tanaka
IMMUNOLOGICAL REVIEWS (2020)
Manufacturing chimeric antigen receptor T cells: issues and challenges
Claire Roddie et al.
CYTOTHERAPY (2019)
Allogenic V9V2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma
Mohammed Alnaggar et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Expansion of human T cells for adoptive immunotherapy using a bisphosphonate prodrug
Yoshimasa Tanaka et al.
CANCER SCIENCE (2018)
Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells
Lin Xiao et al.
CYTOTHERAPY (2018)
Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation
Anna Capsomidis et al.
MOLECULAR THERAPY (2018)
Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression
Chungyong Han et al.
NATURE COMMUNICATIONS (2018)
Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination
Yasushi Akahori et al.
BLOOD (2018)
GITR Agonism Enhances Cellular Metabolism to Support CD8+ T-cell Proliferation and Effector Cytokine Production in a Mouse Tumor Model
Simran S. Sabharwal et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
Alec J. Walker et al.
MOLECULAR THERAPY (2017)
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Justin Eyquem et al.
NATURE (2017)
Targeting Cancer Cells with a Bisphosphonate Prodrug
Kenji Matsumoto et al.
CHEMMEDCHEM (2016)
Immune suppressive mechanisms in the tumor microenvironment
David H. Munn et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome
Linan Wang et al.
ONCOIMMUNOLOGY (2016)
γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytes
Irma Airoldi et al.
BLOOD (2015)
Challenges of cancer therapy with natural killer cells
Hans Klingemann
CYTOTHERAPY (2015)
Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street
David M. Barrett et al.
JOURNAL OF IMMUNOLOGY (2015)
GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo
Alexander Pedroza-Gonzalez et al.
ONCOIMMUNOLOGY (2015)
The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Human Vγ9Vδ2 T Cells
Andrew Sandstrom et al.
IMMUNITY (2014)
Clinical applications of gamma delta T cells with multivalent immunity
Drew C. Deniger et al.
FRONTIERS IN IMMUNOLOGY (2014)
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
Nicoletta Cieri et al.
BLOOD (2013)
Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous γδ T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor
Drew C. Deniger et al.
MOLECULAR THERAPY (2013)
Mechanisms of the Antitumor Activity of Human Vγ9Vδ2 T Cells in Combination With Zoledronic Acid in a Preclinical Model of Neuroblastoma
Emma Di Carlo et al.
MOLECULAR THERAPY (2013)
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy
Maria Themeli et al.
NATURE BIOTECHNOLOGY (2013)
siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions
K. Iwamura et al.
GENE THERAPY (2012)
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
Jun Mitsui et al.
CLINICAL CANCER RESEARCH (2010)
γδ T cell effector functions: a blend of innate programming and acquired plasticity
Marc Bonneville et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling
Hiroyoshi Nishikawa et al.
CANCER RESEARCH (2008)
Zoledronate facilitates large-scale ex vivo expansion of functional gamma delta T cells from cancer patients for use in adoptive immunotherapy
M. Kondo et al.
CYTOTHERAPY (2008)
Estimating In Vivo Death Rates of Targets due to CD8 T-Cell-Mediated Killing
Vitaly V. Ganusov et al.
JOURNAL OF VIROLOGY (2008)
Mathematical models of cytotoxic T-lymphocyte killing
Roland R. Regoes et al.
IMMUNOLOGY AND CELL BIOLOGY (2007)
Human γδ T lymphocytes strip and kill tumor cells simultaneously
Julie Gertner et al.
IMMUNOLOGY LETTERS (2007)
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
P Hoffmann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Human γδ T cells as mediators of chimaeric-receptor redirected anti-tumour immunity
M Rischer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells
HJ Gober et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Share Paper
